Literature DB >> 15942654

Involvement of proteolytic activation of PKCdelta in cisplatin-induced apoptosis in human small cell lung cancer H69 cells.

Shalini D Persaud1, Van Hoang, Jie Huang, Alakananda Basu.   

Abstract

Proteolytic activation of protein kinase C delta (PKCdelta) has been associated with apoptosis induced by the DNA damaging agent cisplatin. In cells undergoing apoptosis, caspase-3 cleaves PKCdelta at the site DMQD downward arrowN to generate a 40-kDa catalytic fragment. We have previously shown that the PKC signal transduction pathway regulates sensitivity of human small cell lung cancer H69 cells to cisplatin. In the present study, we have investigated if proteolytic activation of PKCdelta is essential for cisplatin-induced apoptosis in H69 cells. The caspase cleavage-resistant mutant PKCdelta (DMQA) was generated by mutating the aspartate residue at the site of proteolysis DMQD downward arrowN to alanine (D330A), and the wild-type and mutant PKCdelta were introduced into H69 cells. Cisplatin induced a substantial increase in PKCdelta catalytic fragment in H69 cells overexpressing PKCdelta (H69/delta, and the level of PKCdelta catalytic fragment in H69 cells expressing DMQA mutant (H69/DMQA) was equivalent to that in H69 cells. However, the cleavage of poly(ADP-ribose) polymerase (PARP), another substrate for caspase-3, was similar in cells overexpressing wild-type PKCdelta and DMQA mutant PKCdelta. The ability of cisplatin to induce mitochondrial depolarization and cell death was also equivalent among the cell lines tested. These results suggest that the proteolytic fragment of PKCdelta does not play a critical role in the induction of apoptosis in H69 cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942654

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  Caspase-mediated protein kinase C-delta cleavage is necessary for apoptosis of vascular smooth muscle cells.

Authors:  Kaori Kato; Dai Yamanouchi; Karla Esbona; Kentaro Kamiya; Fan Zhang; K Craig Kent; Bo Liu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-16       Impact factor: 4.733

Review 2.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

3.  Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells.

Authors:  Wei Lu; Susan Finnis; Cunli Xiang; Hae Kyung Lee; Yael Markowitz; Hana Okhrimenko; Chaya Brodie
Journal:  Biochem Biophys Res Commun       Date:  2006-11-16       Impact factor: 3.575

4.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 5.  Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors:  Zhongwei Liu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

Review 6.  Protein kinase C, an elusive therapeutic target?

Authors:  Daria Mochly-Rosen; Kanad Das; Kevin V Grimes
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

7.  Regulation of Transcriptional Networks by PKC Isozymes: Identification of c-Rel as a Key Transcription Factor for PKC-Regulated Genes.

Authors:  Rachana Garg; M Cecilia Caino; Marcelo G Kazanietz
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

8.  PKCδ promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc.

Authors:  Panai Song; Shikun Yang; Li Xiao; Xiaoxuan Xu; Chengyuan Tang; Yuyan Yang; Mingming Ma; Jiefu Zhu; Fuyou Liu; Lin Sun
Journal:  Oxid Med Cell Longev       Date:  2014-10-13       Impact factor: 6.543

9.  Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Authors:  K A Benhadji; M Serova; A Ghoul; E Cvitkovic; C Le Tourneau; S M Ogbourne; F Lokiec; F Calvo; P Hammel; S Faivre; E Raymond
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.